Skip to main content
. 2019 Aug 26;7:223. doi: 10.1186/s40425-019-0693-y

Fig. 8.

Fig. 8

Anti-sMIC therapy with B10G5 up-regulates PD-L1 expression on tumor cells, which is in part NK cell dependent. a, Depletion of NK cells (dpNK) during therapy diminishes the therapeutic effect of co-targeting sMIC and PD-L1 as assessed by prostate weight at necropsy. All treatments were given twice weekly i.p. for 8 weeks. b, Representative histograms from flow cytometry analyses demonstrating the percentage of PD-L1+ tumor cells from TRAMP/MICB mice. c, Summary data of the percentage of PD-L1+ tumor cells from (a)